Findings from Multicenter Study Comparing Derma Sciences’ AMNIOEXCEL® Against Standard-of-Care for Treating Diabetic Foot Ulcers Published in WOUNDS, a Leading Peer-Reviewed Journal

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that a peer-reviewed comparative clinical study of AMNIOEXCEL® Amniotic Allograft Membrane plus standard-of-care (SOC), compared with SOC alone, for the closure of hard-to-treat diabetic foot ulcers, has been published. The results are statistically significant and clinically meaningful, with the closure rate at six weeks in the AMNIOEXCEL® plus SOC treatment arm far exceeding the SOC alone treatment arm.